Zydus Lifesciences reported a 29% revenue jump to Rs 7,909.6 crore for Q2 FY27, fueled by strong growth in its Consumer Wellness and North American segments. However, net profit declined 27% to Rs 925.5 crore as EBITDA margins contracted to 24% from 32.9% in the previous year. Investors are balancing this robust top-line performance against margin pressures and recent USFDA inspection observations at key facilities.
Zydus Lifesciences Q2 FY27: Revenue Up, Margins Down
Revenue grew 29.2% to Rs 7,909.6 crore, while net profit fell 26.6% to Rs 925.5 crore.
Reader Takeaway: Strong revenue expansion in Consumer Wellness and North America is currently offset by significant EBITDA margin compression.
What just happened
Zydus Lifesciences released its financial results for the quarter ending September 30, 2026. While the company achieved impressive sales growth of nearly 30%, profitability took a hit as EBITDA margins dropped by 890 basis points year-on-year to 24%. This divergence between revenue and profit growth has become a focal point for market observers.
Why this matters
The Pharma business continues to dominate, contributing 83% of consolidated revenue, with North American operations delivering a 21% increase. However, the 76% surge in the Consumer Wellness segment highlights the strength of Zydus’s diversification. The sharp decline in bottom-line performance suggests rising operational or input costs that require management's attention.
Innovation and Regulatory Pipeline
The company marked a significant milestone with the USFDA accepting its BLA for a Pembrolizumab biosimilar, the first such filing for a Keytruda biosimilar in the US market. Conversely, USFDA inspections at the SEZ II (Ahmedabad) and Moraiya facilities resulted in one and five observations, respectively. While remediation is underway, these inspections remain a critical watch point for future product approvals.
Risks to watch
Investors should closely monitor the sustainability of margin levels in upcoming quarters and the speed at which the company addresses the recent USFDA regulatory observations. Any delays in resolving these findings could potentially impact the rollout of new drugs in the North American market.
What to track next
Watch for commentary on cost-control measures to stabilize EBITDA margins and updates on the clinical progress of the Saroglitazar Magnesium portfolio in PBC and MASH treatments.